Clinical trial · Observational
Survivin Urine mRNA Assay Risk of Bladder Cancer Study
Evaluation of the Survivin Urine mRNA Assay to Estimate Risk of Bladder Cancer Found on Cystoscopy
NCT00315653CI-TRIAL-00001346completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this clinical trial is to evaluate the ability of urinary Survivin mRNA measurement to estimate the risk of bladder cancer at the time of cystoscopy in subjects with no prior history of bladder cancer presenting with microscopic or macroscopic hematuria.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Able to understand and sign Informed Consent; * Age \>50 years old; * Males or females; * Subjects must have confirmed micro-hematuria, defined as any positive urine reagent strip test for blood (i.e. finding of "Trace" or higher amounts of blood) and/or \>3 RBC per high power field on microscopic examination, or macro-hematuria, defined as visible blood in the urine sample; * All subjects must be scheduled to undergo a cystoscopy evaluation; * All subjects must have upper tract imaging performed within +/- 4 weeks of the cystoscopic evaluation. Exclusion Criteria: * Previous history of bladder cancer; * Previous history of other cancers except for non-melanoma skin cancer; * Prior pelvic radiation; * Active urinary or vaginal infection; * Any evidence of vaginal or rectal bleeding; * Currently receiving chemotherapies such as cyclophosphamide or methotrexate; * Unable to provide informed consent or a high risk that the subject may not comply with the protocol requirements.
References
Publications (0)
Data not yet available
No reference posted for this study.